NDAA Psychedelics Provision: Military Trials Funded

What the NDAA psychedelics provision does

The NDAA psychedelics provision directs the Department of Defense to fund clinical trials of psychedelics for active-duty troops. It lives in Section 723 of the National Defense Authorization Act for Fiscal Year 2024. President Biden signed that bill into law on December 22, 2023.

The provision is narrow on purpose. It does not legalize anything. Instead, it tells the Secretary of Defense to set up a process to pay for research into how certain psychedelics affect service members with combat-related conditions.

It also put the Pentagon on a clock. The law gave the Department of Defense 180 days from enactment to name a lead administrator and start the funding process. This was the first time Congress directly ordered active-duty psychedelic trials in decades.

Why it matters in 2026

Active-duty trials are now actually underway, which makes 2026 a year of early results rather than just promises. The program is also a test case for whether the federal government will treat psychedelics as serious medicine for trauma. Lawmakers have already proposed extending the research authority through 2033 in later defense bills.

Which psychedelics it covers

Section 723 names four psychedelics by name. The Department of Defense can study any of them, plus a broader catch-all category. The covered substances are:

• MDMA — also written 3,4-methylenedioxymethamphetamine; studied for PTSD.
• Psilocybin — the active compound in "magic mushrooms."
• Ibogaine — a plant-derived compound studied for trauma and addiction, and a focus of veterans' groups.
• 5-MeO-DMT — 5-Methoxy-N,N-dimethyltryptamine, a fast-acting tryptamine.

The law also allows "qualified plant-based alternative therapies." That phrase gives the Department of Defense room to add other natural compounds later. For background on the leading candidates, see our guides to MDMA and ibogaine.

Who qualifies — and the hurdles

Only active-duty service members can take part in these trials. The provision does not cover veterans, family members, or the general public. Eligibility is tightly gated, which limits who can actually enroll.

To join a trial, a service member generally must:

• Be on active duty at the time of the study.
• Have a diagnosis of PTSD or traumatic brain injury.
• Receive clearance from the Department of Defense to participate.
• Take the substance only in a controlled clinical setting with a therapist.

These gates matter more than they look. A service member who fears that a psychedelic study could affect a security clearance, a flight status, or a career may simply not volunteer. The clearance requirement and the active-duty cutoff together narrow the real pool far below the number of troops living with PTSD — a practical limit that the headlines about "military psychedelic trials" rarely mention.

The diagnosis rule adds another filter. A member needs a documented PTSD or TBI diagnosis on record to qualify. Many troops avoid seeking that diagnosis in the first place, often to protect their assignments. So the same stigma that drives interest in psychedelic therapy can also keep eligible members out of the very trials meant to help them.

The funding: $10 million, two trials

The Department of Defense has put roughly $10 million toward the program. It announced it was distributing about $4.9 million each for two MDMA trials — one focused on PTSD and one on traumatic brain injury. Together, those grants make up the widely cited $10 million figure.

The $10 million number is worth a careful read. It reflects the money the Department of Defense actually committed, not a dollar amount written into the text of Section 723. The statute orders the research process; the funding level came from how the Pentagon chose to carry it out. We flag this because many summaries treat "$10 million" as if it were appropriated in the bill text itself, which overstates what the words on the page guarantee.

The Department of Defense can also partner with other federal agencies, state agencies, or academic institutions to run the studies. That partner model could stretch the research further than the dollar figure alone suggests.

For context, $10 million is small next to the Pentagon's overall research budget. The point of the provision was less the dollar size and more the precedent: Congress directly ordering active-duty psychedelic trials at all. A modest, focused budget was easier to defend than a large open-ended one, which helped the language survive negotiations.

How the final version was narrowed

The enacted provision was narrower than the broader psychedelic-therapy push that came before it. Rep. Dan Crenshaw had led the Douglas "Mike" Day Psychedelic Therapy to Save Lives Act, named for a Navy SEAL who died by suicide. The House passed psychedelic language in the 2022 NDAA, but the Senate dropped it.

Rep. Morgan Luttrell then authored the version that became Section 723. To win Senate agreement, the final text leaned on tight guardrails: active-duty members only, specific diagnoses, Department of Defense clearance, and controlled clinical settings. The compromise drew unusual cross-party support, including from Reps. Ro Khanna and Alexandria Ocasio-Cortez.

The result is a focused research mandate rather than a sweeping access law. That framing is exactly why it could pass. It also explains why the program's real-world reach is modest compared to the attention it drew.

Research funding vs. legal access

The NDAA provision funds research and changes nothing about legal status. MDMA, psilocybin, ibogaine, and 5-MeO-DMT all remain Schedule I under federal law. Using them outside an authorized trial is still illegal and still against military rules.

This is the same pattern seen across federal psychedelic policy: study first, access later, if at all. Other federal pathways work differently. The Right to Try Act targets terminally ill patients, and a recent executive order on psychedelics signals broader interest. State efforts like the Texas ibogaine bill take yet another route.

If you want to see whether you can join an active study, our clinical trial finder tracks open psychedelic trials, including military and veteran research.

Active-duty DoD trials vs. VA research

The NDAA provision is only one slice of federal psychedelic research. The table below shows how the active-duty Department of Defense effort differs from the separate work happening at the Department of Veterans Affairs.

When the DoD pathway fits: if you are active duty with a qualifying diagnosis and clearance. When VA research fits: if you have separated from service and receive care through the VA. Neither one lets you legally buy or use psychedelics on your own.

Timeline of the provision

• 2022: The House passes psychedelic-research language in the NDAA; the Senate drops it.
• 2023: Rep. Morgan Luttrell authors new NDAA language, building on Rep. Dan Crenshaw's Mike Day Act.
• December 14, 2023: Congress clears the FY2024 NDAA with the psychedelics provision (Section 723) intact.
• December 22, 2023: President Biden signs the FY2024 NDAA into law.
• 2024: The Department of Defense moves to fund two MDMA trials (about $4.9 million each) for PTSD and TBI.
• 2026 onward: Trials run; lawmakers propose extending the research authority through 2033.